A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)

A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)

Background: Bevacizumab (Avastin®, Roche), which is used in cancer therapy, is the ‘parent’ molecule from which ranibizumab (Lucentis®, Novartis) was derived for the treatment of neovascular age-related macular degeneration (nAMD). There were reports in the literature on the effectiveness of bevaciz...

Full description

Bibliographic Details
Main Authors: Usha Chakravarthy, Simon P Harding, Chris A Rogers, Susan Downes, Andrew J Lotery, Helen A Dakin, Lucy Culliford, Lauren J Scott, Rachel L Nash, Jodi Taylor, Alyson Muldrew, Jayashree Sahni, Sarah Wordsworth, James Raftery, Tunde Peto, Barnaby C Reeves
Format: Article
Language:English
Published: NIHR Journals Library 2015-10-01
Series:Health Technology Assessment
Online Access:https://doi.org/10.3310/hta19780

Internet

https://doi.org/10.3310/hta19780

Similar Items